These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36585710)

  • 1. SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF.
    Feng K; Shi Q; Jiao D; Chen Y; Yang W; Su K; Wang Y; Huang Y; Zhang P; Li Y; Wang C
    Cell Biosci; 2022 Dec; 12(1):211. PubMed ID: 36585710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced autophagy and NFE2L2/NRF2 pathway activation in SPOP mutation-driven prostate cancer.
    Gao K; Shi Q; Liu Y; Wang C
    Autophagy; 2022 Aug; 18(8):2013-2015. PubMed ID: 35438056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer.
    Shi Q; Jin X; Zhang P; Li Q; Lv Z; Ding Y; He H; Wang Y; He Y; Zhao X; Zhao SM; Li Y; Gao K; Wang C
    Cell Death Differ; 2022 Jun; 29(6):1228-1239. PubMed ID: 34987184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
    Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
    Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
    Jiang Q; Zheng N; Bu L; Zhang X; Zhang X; Wu Y; Su Y; Wang L; Zhang X; Ren S; Dai X; Wu D; Xie W; Wei W; Zhu Y; Guo J
    Mol Cancer; 2021 Aug; 20(1):100. PubMed ID: 34353330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
    Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
    Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis.
    Ge Y; Jin J; Chen G; Li J; Ye M; Jin X
    Cell Commun Signal; 2023 Oct; 21(1):303. PubMed ID: 37904149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
    Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
    Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.
    Zhang P; Gao K; Jin X; Ma J; Peng J; Wumaier R; Tang Y; Zhang Y; An J; Yan Q; Dong Y; Huang H; Yu L; Wang C
    Cell Death Dis; 2015 Mar; 6(3):e1687. PubMed ID: 25766326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
    Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
    Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
    Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
    J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.
    Jin X; Shi Q; Li Q; Zhou L; Wang J; Jiang L; Zhao X; Feng K; Lin T; Lin Z; Zhuang H; Yang J; Hu C; Zhang L; Shen L; Lu Y; Zhu J; Wang H; Qi H; Meng X; Xi Y; Pan J; Fang S; Tian H; Zhou C; Zhang P; Gao K; Zhao SM; Li Y; Gong Z; Wang C
    Leukemia; 2020 May; 34(5):1305-1314. PubMed ID: 31776466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
    Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
    Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
    PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant SPOP-CHAF1A ubiquitination axis triggers tumor autophagy that endows a therapeutical vulnerability in diffuse large B cell lymphoma.
    Yan W; Shi X; Wang H; Liao A; Yang W
    J Transl Med; 2022 Jun; 20(1):296. PubMed ID: 35773729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
    Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
    Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPOP targets oncogenic protein ZBTB3 for destruction to suppress endometrial cancer.
    Jin X; Wang J; Li Q; Zhuang H; Yang J; Lin Z; Lin T; Lv Z; Shen L; Yan C; Zheng J; Zhu J; Gong Z; Wang C; Gao K
    Am J Cancer Res; 2019; 9(12):2797-2812. PubMed ID: 31911863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
    Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
    Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPOP promotes CREB5 ubiquitination to inhibit MET signaling in liver cancer.
    Gong DA; Zhou P; Chang WY; Yang JY; Zhang YL; Huang AL; Tang N; Wang K
    Biochim Biophys Acta Mol Cell Res; 2024 Feb; 1871(2):119642. PubMed ID: 37996058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.